Literature DB >> 28293734

[Chemotherapy-induced peripheral neuropathy and neuropathic pain].

U Schuler1, S Heller2.   

Abstract

The perception of the media is that chemotherapy is mainly associated with nausea, vomiting and hair loss. In the longer term the development of peripheral neuropathy, i.e. chemotherapy-induced peripheral neuropathy (CIPN) is often more important for patients. The CIPN represents a side effect of many antineoplastic substances with severe functional impairment and its prevention and treatment is an important task. In addition to many interventions, which have been shown to be ineffective, physiotherapeutic measures and possibly the prophylactic application of cold are helpful for prevention. Randomized studies on the treatment of painful CIPN provided positive data for duloxetine and to a lesser extent for venlafaxine.

Entities:  

Keywords:  Duloxetine; Peripheral nervous system diseases, prevention & control; Physical therapy modalities; Platinum compounds; Vinca alkaloids

Mesh:

Substances:

Year:  2017        PMID: 28293734     DOI: 10.1007/s00482-017-0198-x

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  60 in total

1.  Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.

Authors:  J P Durand; G Deplanque; V Montheil; J M Gornet; F Scotte; O Mir; A Cessot; R Coriat; E Raymond; E Mitry; P Herait; Y Yataghene; F Goldwasser
Journal:  Ann Oncol       Date:  2011-03-22       Impact factor: 32.976

2.  Genetic variation associated with bortezomib-induced peripheral neuropathy.

Authors:  Reyna Favis; Yu Sun; Helgi van de Velde; Erin Broderick; Laura Levey; Michael Meyers; George Mulligan; Jean-Luc Harousseau; Paul G Richardson; Deborah S Ricci
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

3.  Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1.

Authors:  Charles L Loprinzi; Brandi N Reeves; Shaker R Dakhil; Jeff A Sloan; Sherry L Wolf; Kelli N Burger; Arif Kamal; Nguyet A Le-Lindqwister; Gamini S Soori; Anthony J Jaslowski; Paul J Novotny; Daniel H Lachance
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

4.  Peripheral neuropathy associated with cis-dichlorodiammineplatinum (II) treatment.

Authors:  D Hadley; H W Herr
Journal:  Cancer       Date:  1979-12       Impact factor: 6.860

5.  Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.

Authors:  Claudio Cartoni; Gregorio Antonio Brunetti; Vincenzo Federico; Fabio Efficace; Sara Grammatico; Andrea Tendas; Laura Scaramucci; Luca Cupelli; Gianna Maria D'Elia; Andrea Truini; Pasquale Niscola; Maria Teresa Petrucci
Journal:  Support Care Cancer       Date:  2012-06-15       Impact factor: 3.603

Review 6.  Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis.

Authors:  Christina Ramsenthaler; Pauline Kane; Wei Gao; Richard J Siegert; Polly M Edmonds; Stephen A Schey; Irene J Higginson
Journal:  Eur J Haematol       Date:  2016-09-06       Impact factor: 2.997

7.  Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia.

Authors:  Sindhu Ramchandren; Marcia Leonard; Rajen J Mody; Janet E Donohue; Judith Moyer; Raymond Hutchinson; James G Gurney
Journal:  J Peripher Nerv Syst       Date:  2009-09       Impact factor: 3.494

8.  A history of cancer chemotherapy.

Authors:  Vincent T DeVita; Edward Chu
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

9.  Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.

Authors:  Makoto Nagashima; Mitsuru Ooshiro; Ayako Moriyama; Yui Sugishita; Kengo Kadoya; Ayami Sato; Tomoaki Kitahara; Ryuichi Takagi; Tasuku Urita; Yutaka Yoshida; Hiroshi Tanaka; Takashi Oshiro; Shinichi Okazumi; Ryoji Katoh
Journal:  Support Care Cancer       Date:  2014-01-24       Impact factor: 3.603

Review 10.  Neuropathic pain: an updated grading system for research and clinical practice.

Authors:  Nanna B Finnerup; Simon Haroutounian; Peter Kamerman; Ralf Baron; David L H Bennett; Didier Bouhassira; Giorgio Cruccu; Roy Freeman; Per Hansson; Turo Nurmikko; Srinivasa N Raja; Andrew S C Rice; Jordi Serra; Blair H Smith; Rolf-Detlef Treede; Troels S Jensen
Journal:  Pain       Date:  2016-08       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.